Revise laws relating to prescription drug supply chain and transparency.

This bill (LC 3549) was a draft proposal to revise laws concerning prescription drug supply chain transparency, but it never advanced beyond the drafting stage. The bill died in committee on May 23, 2025, with no specific provisions or mechanisms described in the available context. Since it was never introduced or debated, no concrete policy changes were defined or implemented. The title indicates it aimed to affect prescription drug supply chain regulations, but no details about affected entities or specific requirements were provided. As a procedural draft that did not progress, no substantive summary can be generated.